EMEA-002723-PIP01-19

Table of contents

Key facts

Active substance
Plasma kallikrein inhibitor
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0416/2020
PIP number
EMEA-002723-PIP01-19
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of hereditary angioedema
Route(s) of administration
Oral use
Contact for public enquiries
KalVista Pharmaceuticals Ltd

E-mail: regulatory@kalvista.com
Tel: +44 1980753002

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating